Hello_老虎社区_美港股上老虎

boon5209
2021-08-31

Hello

AC Immune shares surged more than 70% in early trading<blockquote>AC Immune股价早盘大涨超70%</blockquote>

AC Immune shares surged more than 70% in early trading. AC Immune SA and its collaborating partner

AC Immune shares surged more than 70% in early trading<blockquote>AC Immune股价早盘大涨超70%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":818530182,"tweetId":"818530182","gmtCreate":1630418228046,"gmtModify":1633678211650,"author":{"id":4087435323603320,"idStr":"4087435323603320","authorId":4087435323603320,"authorIdStr":"4087435323603320","name":"boon5209","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hello&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Hello&nbsp;</p></body></html>","text":"Hello","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/818530182","repostId":1174676883,"repostType":4,"repost":{"id":"1174676883","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://www.laohu8.com/m/news/1174676883?lang=zh_CN&edition=full","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading<blockquote>AC Immune股价早盘大涨超70%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p><p><blockquote>AC Immune股价早盘飙升逾70%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>  <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>  <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>  <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>  <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>  <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>  <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li> </ul></p><p><blockquote><ul><li><b>AC免疫SA</b>及其合作夥伴<b>Genentech</b>，部分<b>罗氏控股股份公司</b>宣布了评估semorinemab治疗轻度至中度阿尔茨海默病(AD)的2期研究的顶线数据。</li><li>Semorinemab达到了其共同主要终点之一ADAS-Cog11（认知量表）。第二个共同主要终点ADCS-ADL（功能量表）未达到。</li><li>安全性数据显示，semorinemab耐受性良好，具有可接受的安全性特征，并且没有意外的安全性信号。</li><li>在第49周，与安慰剂相比，Semorinemab显示认知能力从基线下降43.6%的统计学显著减少。</li><li>对降低功能衰退率的另一个共同主要终点没有影响。基因泰克报告称，该研究的开放标签部分将按计划继续进行。</li><li>进一步的分析正在进行中，该公司将在11月的CTAD会议上提交顶线数据。</li><li>Semorinemab是一种在研单克隆抗tau抗体，靶向tau蛋白的N末端部分，旨在与tau结合并减缓其在神经元之间的扩散。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading<blockquote>AC Immune股价早盘大涨超70%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading<blockquote>AC Immune股价早盘大涨超70%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-31 21:41</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p><p><blockquote>AC Immune股价早盘飙升逾70%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>  <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>  <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>  <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>  <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>  <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>  <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li> </ul></p><p><blockquote><ul><li><b>AC免疫SA</b>及其合作夥伴<b>Genentech</b>，部分<b>罗氏控股股份公司</b>宣布了评估semorinemab治疗轻度至中度阿尔茨海默病(AD)的2期研究的顶线数据。</li><li>Semorinemab达到了其共同主要终点之一ADAS-Cog11（认知量表）。第二个共同主要终点ADCS-ADL（功能量表）未达到。</li><li>安全性数据显示，semorinemab耐受性良好，具有可接受的安全性特征，并且没有意外的安全性信号。</li><li>在第49周，与安慰剂相比，Semorinemab显示认知能力从基线下降43.6%的统计学显著减少。</li><li>对降低功能衰退率的另一个共同主要终点没有影响。基因泰克报告称，该研究的开放标签部分将按计划继续进行。</li><li>进一步的分析正在进行中，该公司将在11月的CTAD会议上提交顶线数据。</li><li>Semorinemab是一种在研单克隆抗tau抗体，靶向tau蛋白的N末端部分，旨在与tau结合并减缓其在神经元之间的扩散。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1,"symbols_score_info":{"ACIU":0.9}},"isVote":1,"tweetType":1,"viewCount":1780,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}